Opus Genetics Stock Market Value
| IRD Stock | 4.16 0.57 15.88% |
| Symbol | Opus |
Will Pharmaceuticals sector continue expanding? Could Opus diversify its offerings? Factors like these will boost the valuation of Opus Genetics. Market participants price Opus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Opus Genetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
Understanding Opus Genetics requires distinguishing between market price and book value, where the latter reflects Opus's accounting equity. The concept of intrinsic value - what Opus Genetics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Opus Genetics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Opus Genetics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Opus Genetics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Opus Genetics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Opus Genetics.
| 11/30/2025 |
| 02/28/2026 |
If you would invest 0.00 in Opus Genetics on November 30, 2025 and sell it all today you would earn a total of 0.00 from holding Opus Genetics or generate 0.0% return on investment in Opus Genetics over 90 days. Opus Genetics is related to or competes with Acumen Pharmaceuticals, Seer, Agenus, Inovio Pharmaceuticals, VistaGen Therapeutics, TuHURA Biosciences, and Alector. Opus Genetics is entity of United States More
Opus Genetics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Opus Genetics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Opus Genetics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.67 | |||
| Information Ratio | 0.2276 | |||
| Maximum Drawdown | 22.4 | |||
| Value At Risk | (6.10) | |||
| Potential Upside | 12.29 |
Opus Genetics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Opus Genetics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Opus Genetics' standard deviation. In reality, there are many statistical measures that can use Opus Genetics historical prices to predict the future Opus Genetics' volatility.| Risk Adjusted Performance | 0.1955 | |||
| Jensen Alpha | 1.3 | |||
| Total Risk Alpha | 0.7502 | |||
| Sortino Ratio | 0.2649 | |||
| Treynor Ratio | 6.12 |
Opus Genetics February 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1955 | |||
| Market Risk Adjusted Performance | 6.13 | |||
| Mean Deviation | 4.21 | |||
| Semi Deviation | 3.89 | |||
| Downside Deviation | 4.67 | |||
| Coefficient Of Variation | 409.56 | |||
| Standard Deviation | 5.44 | |||
| Variance | 29.58 | |||
| Information Ratio | 0.2276 | |||
| Jensen Alpha | 1.3 | |||
| Total Risk Alpha | 0.7502 | |||
| Sortino Ratio | 0.2649 | |||
| Treynor Ratio | 6.12 | |||
| Maximum Drawdown | 22.4 | |||
| Value At Risk | (6.10) | |||
| Potential Upside | 12.29 | |||
| Downside Variance | 21.85 | |||
| Semi Variance | 15.14 | |||
| Expected Short fall | (4.69) | |||
| Skewness | 0.5524 | |||
| Kurtosis | 0.5224 |
Opus Genetics Backtested Returns
Opus Genetics is unstable given 3 months investment horizon. Opus Genetics maintains Sharpe Ratio (i.e., Efficiency) of 0.24, which implies the firm had a 0.24 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.35% are justified by taking the suggested risk. Use Opus Genetics Risk Adjusted Performance of 0.1955, semi deviation of 3.89, and Coefficient Of Variation of 409.56 to evaluate company specific risk that cannot be diversified away. Opus Genetics holds a performance score of 19 on a scale of zero to a hundred. The company holds a Beta of 0.22, which implies not very significant fluctuations relative to the market. As returns on the market increase, Opus Genetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Opus Genetics is expected to be smaller as well. Use Opus Genetics expected short fall, and the relationship between the value at risk and daily balance of power , to analyze future returns on Opus Genetics.
Auto-correlation | -0.18 |
Insignificant reverse predictability
Opus Genetics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Opus Genetics time series from 30th of November 2025 to 14th of January 2026 and 14th of January 2026 to 28th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Opus Genetics price movement. The serial correlation of -0.18 indicates that over 18.0% of current Opus Genetics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.18 | |
| Spearman Rank Test | -0.27 | |
| Residual Average | 0.0 | |
| Price Variance | 0.37 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Opus Genetics is a strong investment it is important to analyze Opus Genetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Opus Genetics' future performance. For an informed investment choice regarding Opus Stock, refer to the following important reports:Check out Opus Genetics Correlation, Opus Genetics Volatility and Opus Genetics Performance module to complement your research on Opus Genetics. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Opus Genetics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.